|
NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer |
|
EC122 HER-1 Prostate Phase I |
|
NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer |
|
D004 vs terazosin |
|
1B8 vs MabThera® in patients with Diffuse large B-cell lymphoma |
|
Nimotuzumab inoperable esophageal epithelial tumors, Phase IV |
|
COURAGE Study |
|
NAcGM3/VSSP-aids-patients drug resistant to antiretroviral treatment-Phase I-II |
|
Biograft-G in Dentistry |
|
Dermofural-diabetic foot ulcers |
|
Determination of the local inflammatory response in patients with COPD by wood smoke and COPD per cigarette |
|
CIGB-370 in patients with malignant tumors |
|
Predictor of response with CIMAvax EGF© in NSCLC Phase III |
|
Vaxira as adjuvant treatment for non-small cell lung cancer |
|
Racotumomab-alum cancer vaccine for solid tumors in pediatric patients |
|
CIMAvax-EGF vaccine Predictor Phase IV |
|
Dose scale-up and cohort expansion with the therapeutic mAb 14F7 |
|
Study of the meningococcal ACW135 polysaccharide vaccine |
|
EFFECTIVENESS AND SAFETY IN GENERIC ABACAVIR/LAMIVUDINE AND EFAVIRENZ IN HIV NAIVE PATIENTS |
|
Itolizumab for Moderate-to-Severe Psoriasis-phase 3 |
